April 12, 2018

Halo Pharma Simplifies Topical Drug Product Development and Manufacturing

Global Pharmaceutical Companies Outsource Topical Products to Halo Pharma

Whippany, N.J., April 12, 2018 – Halo Pharma, a rapidly growing contract development and manufacturing organization (CDMO), offers more than 30 years’ direct experience in the production of topical drug products – from prescription dermatological drugs to over-the-counter (OTC) and high-value health and beauty products. Halo Pharma will be discussing its capabilities in topical drug products at CPhI NA, Booth 1549, at the Pennsylvania Convention Center, April 24-26.

Read More
April 5, 2018

Halo Pharma Shares Expertise on Fixed-Dose Combination Products as an Effective Approach to Simplified Dosing

Halo Pharma Shares Expertise on Fixed-Dose Combination Products as an Effective Approach to Simplified Dosing

Whippany, NJ, April 5, 2018 – Halo Pharma (Halo), a rapidly growing contract development and manufacturing organization, will share its expertise in fixed-dose combination (FDC) products as an effective approach for simplified dosing at CPhI NA 2018. CPhI North America’s is a leading conference for the entire pharmaceutical ecosystem. Dr. Anthony Qu, Halo’s vice president of scientific affairs, is scheduled to speak at 3:15 p.m., Wednesday, April 25, Room 119A at the Pennsylvania Convention Center in Philadelphia.

Read More
November 2, 2017

Halo Pharma Partners with Pharmaceutical Companies to Formulate and Manufacture a Broad Range of Fixed-Dose Combination Drug Products

Halo-Produced FDC Drugs Already Approved and in Development Benefit Patients, Reduce Costs, and Can Extend Patent Life and Market Dominance

Whippany, NJ, November 2, 2017 - Halo Pharma ("Halo") provides its pharmaceutical manufacturing partners the technical expertise, and advanced formulation technology to support the development and manufacturing of fixed-dose combination (FDC) drugs, a rapidly growing market niche that offers significant advantages across the healthcare spectrum. FDC drugs combine multiple active pharmaceutical ingredients (APIs) into a single-dose product, improving patient convenience and the likelihood for medication compliance and appropriate dosing. Pharma companies can realize substantial savings when developing an FDC comprised of previously approved new chemical entities or their generic counterparts. Bringing to market a FDC product is a proven and attractive strategy for extending the market potential of proprietary drugs.

Read More
September 12, 2017

Halo Pharma Makes Donation to the American Red Cross and Encourages Others to Help Those Affected by Hurricanes Harvey and Irma

Halo Pharma (“Halo”) has made a donation to the American Red Cross to support the humanitarian organization's ongoing efforts to provide emergency aid and disaster relief for the people affected by Hurricane Harvey and Hurricane Irma. In response to natural disasters such as the recent hurricanes, the American Red Cross is typically one of the first groups on the scene, prepared to provide shelter, health services, food, and other forms of disaster relief.

Read More
June 26, 2017

Halo Pharma Welcomes Itzhak Krinsky, Ph.D. to Its Board of Directors

Halo Pharma, a rapidly growing Contract Development and Manufacturing Organization (CDMO), is pleased to announce that Dr. Itzhak Krinsky has joined its Board of Directors. Dr. Krinsky has broad-based expertise in the pharmaceutical industry, years of experience in investment banking, and a distinguished academic career in finance and business economics. Dr. Krinsky developed extensive knowledge of the pharmaceutical industry during his 12 years of working at Teva Pharmaceutical Industries Ltd., from which he retired earlier this year.

Read More
May 10, 2017

Halo Pharma’s Pediatric Center of Excellence

Whippany, NJ, May 10, 2017 - Halo Pharma announces the formation of its Pediatric Center of Excellence in support of the development and manufacture of dosage forms tailored for pediatric indications. Halo Pharma has been working closely with pharmaceutical companies to apply its extensive expertise in formulation sciences and its fully integrated manufacturing capabilities across a broad range of scales and dosage forms to overcome the challenges in developing pediatric dosage forms (PDFs) of already approved adult dosage forms. Halo Pharma is proud to be the manufacturer of choice for many of today’s largest pharma companies having been selected to reformulate multiple products across a variety of dosage forms. Companies have come to rely on Halo Pharma as a trusted partner to provide specialized contract development and manufacturing services that meet the regulatory requirements of the U.S., Canada, and Europe, where Halo Pharma is already manufacturing PDFs for commercial sale through its sponsors.

Read More
February 1, 2017

Halo Pharma is selected by Mezzion Pharma for Phase 3 Manufacturing of udenafil

Mezzion hired Pol Pharma and Halo Pharma to replace former contractor Dr. Reddy's which it says hid manufacturing problems that prompted the US FDA rejects its erectile dysfunction candidate, udenafil.

Read More
August 25, 2015

Halo Pharma Makes Key Additions To Management Team

Halo Pharma, a rapidly growing Contract Development and Manufacturing Organization (CDMO) is pleased to announce the appointments of Lee Karras as its Chief Executive Officer and Barry Lederman as its Chief Financial Officer.

Read More
January 6, 2015

SK Capital Makes Strategic Investment in Halo Pharma.

SK Capital Partners, a private investment firm with a disciplined focus on the specialty materials, chemicals and healthcare sectors, announced today that it has completed a controlling strategic growth investment in Halo Pharma, a premiere provider of outsourced development and manufacturing services to the global pharmaceutical industry. The strategic investment is consistent with SK Capital's sector-focused strategy of investing in niche market leaders with strong brands and technologies and actively supporting management in building thriving businesses with sustainable competitive advantages. Halo Pharma is the sixth platform company in SK Capital Partners Fund III.

Read More